In certain cancers, HER2 becomes overexpressed or uncontrolled, driving tumors to develop quickly. As our understanding of HER2 and its role deepens, its relevance across endometrial, ovarian and other gynecologic tumors has become…
Informed patients are empowered patients. Which is why helping people with cancer understand their disease, as well as how available treatment options might work for them, is a critical focus of our patient advocacy efforts.
Business development is the craft of making connections. Whether with other companies or within our organization, we need to build those bonds that allow us to be successful.
Cancer research and development is a dynamic and ever-evolving field. One significant area of focus is the role of HER2.
The Galien Foundation has recognized Daiichi Sankyo’s HER2 directed antibody drug conjugate (ADC) with the prestigious 2024 Prix Galien USA Award for Best Biotechnology Product.
For cancer patients, the science concerning their disease is sometimes outside of reach. As a patient-centric organization, we are on a mission to break down those barriers.
Cancer remains one of the most challenging diseases in the world today, but critical advances in science are transforming options for more personalized treatment.